They state that the etiology and pathogenesis of most orofacial chronic pain conditions is still unresolved, and they highlight recent findings indicating that nonneural cells,

specifically satellite cells in the sensory ganglia and astroglia and microglia cells in the central nervous system, are important players in both acute and chronic inflammatory and neuropathic orofacial pain conditions.

They ask attention for these new targets for management of these conditions. ^[1]

Meanwhile the gliamodulator palmitoylethanolamide has been shown to be effective in safe in the treatment of the chronic painsyndome of Costen, supporting their statement.

June 2011, Jan M. Keppel Hesselink, MD, PhD 

Referenties